Search | Page 6 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.

    ... has proven efficacy and safety and has been shown to reduce transfusion requirements and reverse cytogenetic abnormalities in lower-risk ... of these patients had an ongoing requirement for red blood cell transfusions despite previous treatment with recombinant ...

    Research Article last updated 10/11/2011 - 5:58pm.

  2. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

    ... Journal Title:  Blood Primary Author:  ... six patients received at least one red blood cell transfusion . Lack of detectable CH50 activity (defined by CH50 ≤10% of ...

    Research Article last updated 01/20/2015 - 2:28pm.

  3. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

    ... Journal Title:  Blood Primary Author:  ... , presence of circulating blasts, and red blood cell transfusion dependency ≥ 4 units/8 weeks (all P < 10(-4)) independently ...

    Research Article last updated 07/28/2014 - 8:53am.

  4. Front-line immunosuppressive treatment of acquired aplastic anemia

    ... 60 and 80%. CsA should be given for 12 months until transfusion independence is achieved and then tapered very slowly in the ... are usually continued on CsA. Tight monitoring of the blood count during CsA tapering is necessary to identify early loss of ...

    Research Article last updated 01/02/2013 - 2:48pm.

  5. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

    ... patients reached HI-E (p=0.07); 48% and 20% achieved transfusion independence (p=0.01). Median OS was 19.6months in the ESA and ... and duration, and of our proposed azacitidine risk score (Blood 2011;117:403-11). Adding an ESA to azacitidine in higher-risk MDS should ...

    Research Article last updated 07/28/2014 - 9:30am.

  6. 5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline.

    ... of hematopoiesis that results in peripheral blood cytopenias and a marked propensity to progress to acute myelogenous ... Although supportive or palliative measures such as blood transfusion have long been the mainstay of management of MDS, ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes.

    ... to this approach. Patients may require frequent blood and platelet transfusion support which is expensive and inconvenient. Life-threatening ... agents can provide a new therapeutic option for enhancing blood production. In this review, we discuss these recent results and ongoing ...

    Research Article last updated 06/20/2013 - 10:13am.

  8. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

    ... 16 weeks, respectively. RESULTS: Rates of red blood cell - transfusion independence (RBC-TI) ≥182 days were higher in the ...

    Research Article last updated 07/29/2014 - 12:12pm.

  9. Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes

    ... placement (ORadj=6.47, 95% CI: 2.37, 17.62) and red blood cell transfusion (ORadj=4.60, 95% CI: 2.29, 9.23) were associated with deep vein ...

    Research Article last updated 12/05/2011 - 10:09am.

  10. Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going

    ... of hematopoietic stem cells and progeny mature blood cells which are deficient in some surface proteins, including the two ... clinical benefit. Anti-complement treatment allowed transfusion independence in at least half of PNH patients receiving ...

    Research Article last updated 05/22/2014 - 8:24am.